Please login to the form below

Not currently logged in
Email:
Password:

trebananib

This page shows the latest trebananib news and features for those working in and with pharma, biotech and healthcare.

Takeda hands back rights to two Amgen drugs

Takeda hands back rights to two Amgen drugs

However, Takeda has decided it is no longer interested in developing pain candidate fulranumab (AMG403) and trebananib (AMG386), which is being tested in cancer. ... In the case of trebananib the picture seems clearer - the compound has already failed

Latest news

  • Amgen's trebananib misses survival target in ovarian cancer Amgen's trebananib misses survival target in ovarian cancer

    Amgen's trebananib misses survival target in ovarian cancer. First phase III trial improved survival rates by just one month. ... he described the overall survival data from TRINOVA-1 as a "binary event" for the trebananib programme.

  • Late-stage ovarian cancer Late-stage ovarian cancer

    Trebananib appears to be closer than nintedanib to approval, given that the primary endpoint (PFS) was achieved in the phase III TRINOVA-1 trial. ... In this trial, 919 patients with recurrent ovarian, primary peritoneal or fallopian tube cancers were

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics